- Home
- LUCY vs SBFM Comparison
LUCY vs SBFM Comparison
Compare LUCY & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- SBFM
- Stock Information
- Founded
- LUCY 2017
- SBFM 2006
- Country
- LUCY United States
- SBFM United States
- Employees
- LUCY N/A
- SBFM N/A
- Industry
- LUCY Ophthalmic Goods
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- SBFM Health Care
- Exchange
- LUCY Nasdaq
- SBFM Nasdaq
- Market Cap
- LUCY 18.5M
- SBFM 3.7M
- IPO Year
- LUCY 2022
- SBFM N/A
- Fundamental
- Price
- LUCY $6.90
- SBFM $3.14
- Analyst Decision
- LUCY Strong Buy
- SBFM
- Analyst Count
- LUCY 1
- SBFM 0
- Target Price
- LUCY $20.00
- SBFM N/A
- AVG Volume (30 Days)
- LUCY 104.1K
- SBFM 90.8K
- Earning Date
- LUCY 11-12-2024
- SBFM 11-11-2024
- Dividend Yield
- LUCY N/A
- SBFM N/A
- EPS Growth
- LUCY N/A
- SBFM N/A
- EPS
- LUCY N/A
- SBFM N/A
- Revenue
- LUCY $1,529,782.00
- SBFM $30,481,982.00
- Revenue This Year
- LUCY $245.17
- SBFM $86.70
- Revenue Next Year
- LUCY $258.97
- SBFM $126.76
- P/E Ratio
- LUCY N/A
- SBFM N/A
- Revenue Growth
- LUCY 186.54
- SBFM 109.82
- 52 Week Low
- LUCY $3.26
- SBFM $2.42
- 52 Week High
- LUCY $27.20
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- LUCY 44.95
- SBFM 52.62
- Support Level
- LUCY $6.33
- SBFM $2.85
- Resistance Level
- LUCY $6.89
- SBFM $3.05
- Average True Range (ATR)
- LUCY 0.59
- SBFM 0.14
- MACD
- LUCY -0.27
- SBFM 0.03
- Stochastic Oscillator
- LUCY 14.46
- SBFM 85.29
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.